Leis Elina, Modhukur Vijayachitra, Lust Helen, Vardja Markus, Saarma Merilin, Ilves Ivar, Pütsepp Margaret, Kopanchuk Sergei, Jaal Jana, Lavogina Darja
Department of Haematology and Oncology, Institute of Clinical Medicine, University of Tartu, L. Puusepa 8, 50406, Tartu, Estonia.
Department of Radiotherapy and Oncological Therapy, Tartu University Hospital, Tartu, Estonia.
Sci Rep. 2025 Jul 7;15(1):24245. doi: 10.1038/s41598-025-09285-4.
Lung cancer is the leading cause of cancer-related mortality globally, with non-small cell lung cancer (NSCLC) representing 85% of cases. Advances in treatment modalities, including stereotactic radiation therapy, have improved outcomes. However, possible synergistic effects of these therapies remain underexplored at the molecular level. This study investigated high-dose radiation-induced proteomic changes in lung adenocarcinoma cell line HCC-44 grown adherently and cell line A549, grown as adherent cells or spheroids. Our hypothesis was that proteins upregulated by 10 Gy irradiation serve as resistance drivers in cancerous cells and can thus represent potential therapeutic targets. The label-free mass spectrometry revealed distinct proteomic responses to 10 Gy irradiation, varying by cell line and culturing conditions. Differentially expressed proteins elevated in the irradiated samples included ephrin type-A receptor 2 (EPHA2) in adherent cells and insulin-like growth factor 2 receptor, tetraspanin 3 as well as cathepsin D (CTSD) in spheroids. The validation of these targets was carried out via Western blot, immunofluorescence, viability assay and spheroid formation assay which demonstrated that irradiation sensitized adherent NSCLC cells to EPHA2 and CTSD inhibitors. These findings underscore the potential of integrating radiation and targeted therapies in NSCLC treatment, and highlight EPHA2 as a promising candidate for future therapeutic strategies.
肺癌是全球癌症相关死亡的主要原因,其中非小细胞肺癌(NSCLC)占病例的85%。包括立体定向放射治疗在内的治疗方式的进步改善了治疗结果。然而,这些疗法在分子水平上可能的协同作用仍未得到充分探索。本研究调查了高剂量辐射对贴壁生长的肺腺癌细胞系HCC-44以及贴壁生长或形成球体的细胞系A549所诱导的蛋白质组学变化。我们的假设是,受10 Gy照射上调的蛋白质是癌细胞中的耐药驱动因素,因此可作为潜在的治疗靶点。无标记质谱分析揭示了对10 Gy照射的不同蛋白质组学反应,这些反应因细胞系和培养条件而异。照射样本中上调的差异表达蛋白包括贴壁细胞中的 Ephrin A 型受体 2(EPHA2)以及球体中的胰岛素样生长因子 2 受体、四跨膜蛋白 3 和组织蛋白酶 D(CTSD)。通过蛋白质免疫印迹、免疫荧光、活力测定和球体形成测定对这些靶点进行了验证,结果表明照射使贴壁的NSCLC细胞对EPHA2和CTSD抑制剂敏感。这些发现强调了在NSCLC治疗中整合放射治疗和靶向治疗的潜力,并突出了EPHA2作为未来治疗策略的一个有前景的候选靶点。
Psychopharmacol Bull. 2024-7-8
J Nanobiotechnology. 2025-6-16
Cell Mol Biol Lett. 2024-9-27
Cell Death Discov. 2024-4-22